A double-blind, randomized, single-center, two treatment, four period, two sequence, replicate crossover, euglycemic clamp study to demonstrate equivalence in the Pharmacokinetic and Pharmacodynamic properties of Insulin Glargine injection 100IU/mL of Stelis Biopharma and LANTUS® (Insulin Glargine injection 100 IU/mL of Sanofi Aventis) in healthy, adult, human subjects under fasting condition. - Nil
100 项与 STLI-001 相关的专利(医药)